Free Trial

HealthEquity, Inc. (NASDAQ:HQY) Director Frank Corvino Sells 1,039 Shares

HealthEquity logo with Medical background

HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total transaction of $99,847.90. Following the transaction, the director now owns 3,784 shares in the company, valued at approximately $363,642.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Frank Corvino also recently made the following trade(s):

  • On Tuesday, October 1st, Frank Corvino sold 1,247 shares of HealthEquity stock. The shares were sold at an average price of $80.26, for a total value of $100,084.22.

HealthEquity Price Performance

Shares of HQY stock traded up $1.62 on Friday, reaching $98.82. The company's stock had a trading volume of 666,790 shares, compared to its average volume of 568,123. The company has a market capitalization of $8.63 billion, a price-to-earnings ratio of 82.35, a price-to-earnings-growth ratio of 1.53 and a beta of 0.52. The stock's fifty day simple moving average is $83.15 and its 200-day simple moving average is $80.44. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 1 year low of $62.10 and a 1 year high of $99.57.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The firm had revenue of $299.93 million for the quarter, compared to analysts' expectations of $284.48 million. Analysts forecast that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on HQY. Royal Bank of Canada reaffirmed an "outperform" rating and set a $92.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Bank of America decreased their price target on shares of HealthEquity from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, September 4th. JMP Securities restated a "market outperform" rating and issued a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. Barrington Research reissued an "outperform" rating and set a $105.00 price target on shares of HealthEquity in a report on Friday, September 20th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of HealthEquity from $102.00 to $103.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $103.83.

Get Our Latest Report on HQY

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in shares of HealthEquity in the second quarter worth approximately $35,000. Paladin Wealth LLC purchased a new stake in HealthEquity in the third quarter worth $39,000. GAMMA Investing LLC lifted its position in shares of HealthEquity by 114.8% during the second quarter. GAMMA Investing LLC now owns 595 shares of the company's stock worth $51,000 after purchasing an additional 318 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity during the second quarter valued at $73,000. Finally, 1620 Investment Advisors Inc. bought a new position in shares of HealthEquity in the third quarter worth about $112,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Articles

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

→ War on Elon Escalates… (From Porter & Company) (Ad)

Should you invest $1,000 in HealthEquity right now?

Before you consider HealthEquity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.

While HealthEquity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines